Suppr超能文献

1 型糖尿病患者的肌肉和血清肌肉抑制素表达。

Muscle and serum myostatin expression in type 1 diabetes.

机构信息

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.

Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada.

出版信息

Physiol Rep. 2020 Jul;8(13):e14500. doi: 10.14814/phy2.14500.

Abstract

Type 1 diabetes (T1D) has been reported to negatively affect the health of skeletal muscle, though the underlying mechanisms are unknown. Myostatin, a myokine whose increased expression is associated with muscle-wasting diseases, has not been reported in humans with T1D but has been demonstrated to be elevated in preclinical diabetes models. Thus, the purpose of this study was to determine if there is an elevated expression of myostatin in the serum and skeletal muscle of persons with T1D compared to controls. Secondarily, we aimed to explore relationships between myostatin expression and clinically important metrics (e.g., HbA , strength, lean mass) in women and men with (N = 31)/without T1D (N = 24) between 18 and 72 years old. Body composition, baseline strength, blood sample and vastus lateralis muscle biopsy were evaluated. Serum, but not muscle, myostatin expression was significantly elevated in those with T1D versus controls, and to a greater degree in T1D women than T1D men. Serum myostatin levels were not significantly associated with HbA nor disease duration. A significant correlation between serum myostatin expression and maximal voluntary contraction (MVC) and body fat mass was demonstrated in control subjects, but these correlations did not reach significance in those with T1D (MVC: R = 0.64 controls vs. R = 0.37 T1D; Body fat: R = -0.52 controls/R = -0.02 T1D). Collectively, serum myostatin was correlated with lean mass (R = 0.45), and while this trend was noted in both groups separately, neither reached statistical significance (R = 0.47 controls/R = 0.33 T1D). Overall, while those with T1D exhibited elevated serum myostatin levels (particularly females) myostatin expression was not correlated with clinically relevant metrics despite some of these relationships existing in controls (e.g., lean/fat mass). Future studies will be needed to fully understand the mechanisms underlying increased myostatin in T1D, with relationships to insulin dosing being particularly important to elucidate.

摘要

1 型糖尿病(T1D)已被报道会对骨骼肌健康产生负面影响,但具体机制尚不清楚。肌生成抑制素是一种肌因子,其表达增加与肌肉消耗性疾病有关,但尚未在 T1D 患者中报道,而在临床前糖尿病模型中已被证明升高。因此,本研究的目的是确定与对照组相比,T1D 患者的血清和骨骼肌中肌生成抑制素是否表达升高。其次,我们旨在探索 T1D 患者(N=31)/无 T1D 患者(N=24)的肌生成抑制素表达与临床重要指标(如 HbA1c、力量、瘦体重)之间的关系,这些患者年龄在 18 至 72 岁之间。评估了身体成分、基线力量、血液样本和股外侧肌活检。结果显示,与对照组相比,T1D 患者的血清肌生成抑制素表达显著升高,且 T1D 女性的升高程度大于 T1D 男性。血清肌生成抑制素水平与 HbA1c 或疾病持续时间无显著相关性。在对照组中,血清肌生成抑制素表达与最大自主收缩(MVC)和体脂肪量之间存在显著相关性,但在 T1D 患者中这些相关性没有达到显著水平(MVC:R=0.64 对照组 vs. R=0.37 T1D;体脂肪:R=-0.52 对照组/R=-0.02 T1D)。总的来说,血清肌生成抑制素与瘦体重呈正相关(R=0.45),尽管在两组中均观察到这种趋势,但均未达到统计学意义(R=0.47 对照组/R=0.33 T1D)。总体而言,尽管 T1D 患者表现出血清肌生成抑制素水平升高(尤其是女性),但肌生成抑制素表达与临床相关指标无关,尽管对照组中存在一些这些关系(例如,瘦/脂肪量)。需要进一步的研究来全面了解 T1D 中肌生成抑制素升高的机制,特别是阐明与胰岛素剂量之间的关系尤为重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb74/7354085/e8bbd7904262/PHY2-8-e14500-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验